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Abstract
Early detection of precancerous tissue has significantly improved survival of most cancers including colorectal
cancer (CRC). Animal models designed to study the early stages of cancer are valuable for identifying molecular
events and response indicators that correlate with the onset of disease. The goal of this work was to investigate
magnetic resonance (MR) colonography in a mouse model of CRC on a clinical MR imager. Mice treated with azoxy-
methane and dextran sulfate sodium were imaged by serial MR colonography (MRC) from initiation to euthanasia.
Magnetic resonance colonography was obtained with both T1- and T2-weighted images after administration of a
Fluorinert enema to remove residual luminal signal and intravenous contrast to enhance the colon wall. Individual
tumor volumes were calculated and validated ex vivo. The Fluorinert enema provided a clear differentiation of the
lumen of the colon from the mucosal lining. Inflammation was detected 3 days after dextran sulfate sodium exposure
and subsided during the next week. Tumors as small as 1.2 mm3 were detected and as early as 29 days after initia-
tion. Individual tumor growths were followed over time, and tumor volumes were measured by MR imaging corre-
lated with volumes measured ex vivo. The use of a Fluorinert enema during MRC in mice is critical for differentiating
mural processes from intraluminal debris. Magnetic resonance colonography with Fluorinert enema and intravenous
contrast enhancement will be useful in the study of the initial stages of colon cancer and will reduce the number of
animals needed for preclinical trials of prevention or intervention.
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Introduction
Colorectal cancer (CRC) is the third most common cancer in the
United States [1,2]. It has been estimated that in 2008 there will
be 148,810 new cases of CRC and 49,960 deaths due to CRC
[1,2]. Whereas the 5-year survival rate for patients with early stage
disease is 90%, more than 57% of patients with newly diagnosed
CRC already have regional or distant metastasis at the time of diag-
nosis [3]. Prognosis becomes increasingly worse with a more ad-
vanced disease with a 5-year survival rate of only 10% for those
with distant metastases. Thus, early detection of colon cancer is vital
to increase survival in CRC.
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Currently, there are several tests commonly used to screen for
CRC, including the fecal occult blood test, digital rectal examination,
sigmoidoscopy, barium enema, colonoscopy, and, most recently, com-
puted tomographic (CT) colonography. The fecal occult blood test is
limited in its sensitivity for early disease. The digital rectal examination
and sigmoidoscopy examine only a limited anatomic section of the
colon. Barium enema is a projection technique that is insensitive for
early polyps. Colonoscopy allows visualization of the entire colon and
detection of aberrant crypt foci (ACF), polyps, and CRC. A particular
advantage of colonoscopy is that biopsy can be performed during the
examination. The disadvantages of colonoscopy include an unpleasant
bowel preparation, the need for sedation, and the potential perforation
of the bowel. Moreover, the accuracy of a colonoscopy depends on
the skill of the operator to visualize all surfaces of the colon. More re-
cently, magnetic resonance (MR) and CT colonographies are being ex-
plored as complementary or alternatives for optical colonoscopy. Both
MR and CT colonographies often include computer-generated “fly-
throughs” of the colon referred to as “virtual colonoscopy.” Both offer
a less demanding alternative for the patient and allow complete visu-
alization of the colonic surface after the bowel is distended with an
enema or with a gas such as air or carbon dioxide.
Recently, animal models of cancer have been engineered to study
cancer prevention and early detection [4]. Whereas many of these
models take advantage of genetically engineered mice (GEM), the
early stages of cancer, starting at the initiated cell, can also be fol-
lowed after chemically induced carcinogenesis. Chemically induced
mouse models of colon cancers result in a more predictable tumor
formation that closely resembles the sequence found in human colon
cancer [5]. The inflammation-carcinoma model is based on the ad-
ministration of azoxymethane (AOM), a genotoxic colonic carcino-
gen, to initiate tumorigenesis followed by dextran sulfate sodium
(DSS), an irritant to the colon that induces colitis and promotes
tumorigenesis. After 20 weeks, the colon of mice treated in this man-
ner reveal ACF, dysplastic lesions, adenomas, and adenocarcinomas.
These lesions have elevated β-catenin, cyclooxygenase 2, and induc-
ible nitric oxide synthase activity [5]. In this two-stage tumor promo-
tion model, a single cycle of 5 to 7 days of exposure to DSS in the
drinking water followed by 16 days of normal water is used to induce
inflammation of the colon and promote adenoma and subsequent
adenocarcinoma formation. By increasing the number of DSS cycles
to three, chronic inflammation, which resembles ulcerative colitis or
Crohn disease, occurs [6].
Whereas the AOM/DSS model is suitable for intervention studies
and can be useful for characterizing both pharmaceutical as well as
dietary responses, currently, the mice must be euthanized and their
colons must be examined pathologically. Thus, a large number of
mice are needed for time course or dose response studies and the pro-
gression of disease must be surmised based on different cohorts of
animals. Earlier detection of tumor development in live mice that
are serially followed with MR colonography (MRC) would reduce
the number of mice needed and the time required to perform pre-
vention studies. Repeated imaging of live mice will allow visualiza-
tion of the tumors as they develop, thus improving understanding
of colonic carcinogenesis as well as providing an early indication of
efficacy of treatments and more accurate timing for euthanasia for
pathologic analysis.
This study describes a method of studying a mouse model of colon
carcinogenesis using MRC. A 3.0-T clinical MR imaging (MRI)
scanner was adapted for animal use using a dedicated solenoid re-
ceiver coil [7]. T2-weighted (T2W) coronal imaging of the colon
in the anesthetized mouse was used for detecting acute inflammation.
To distend the colon and remove unwanted luminal signal [8,9], an
FC-77 Fluorinert enema was used. Fluorinert is an inert, fully fluo-
rinated, nontoxic liquid, which eliminates any MR signal and allows
dark lumen imaging with both T1Wand T2W imaging. Intravenous
gadolinium chelate permitted the enhancement of the bowel wall,
inflammation, and tumors. Tumors were detected as early as 29 days
after initiation and as small as 1.2 mm3. The ability to perform dark
lumen, contrast-enhanced MRC on a clinical scanner in live animals
suggests the potential to translate these studies to the clinic and its
valuable for identifying molecular events and response indicators that
correlate with the early stages of tumor development.
Materials and Methods
Animals
All animal studies were conducted according to the guidelines set
by the Animal Care and Use Committee, NCI-Frederick. Pathogen-
free FVB/N mice were purchased from the NCI-Frederick Animal
Production Area at 5 weeks of age and were exposed to a 12:12–hour
light/dark cycle. Mice were given an AIN-96G purified diet from
Harlan Teklad (Madison, WI) and drinking water ad libitum. At
6 weeks of age, mice were injected intraperitoneally with AOM (Sigma,
St. Louis, MO) at a dose of 10 mg/kg body weight in 0.1 ml of saline
(Figure 1). One week later, mice were started on the first cycle of 0,
1%, or 2% DSS 36,000 to 50,000 (MP Biomedicals LL, Solon, OH)
dissolved in normal drinking water (reverse osmosis–purified water).
Each DSS cycle consists of 5 days with DSS in the drinking water fol-
lowed by 16 days of normal drinkingwater. To ensure 100% tumor inci-
dence, some of the animals were treated with a second DSS cycle.
Reagents
Gadopentetate dimeglumine (Gd-DTPA) Magnevist (Bayer Health-
Care Pharmaceuticals, Wayne, NJ) was diluted in phosphate-buffered
saline (137 mMNaCl, 10 mM phosphate, 2.7 mM KCl, pH 7.4) to a
final concentration 80 mM Gd and 50 μl was injected intravenously
Figure 1. Timeline for AOM/DSS treatment. Day 0: mice were injected with a single dose of AOM. Days 7 to 12: mice were treated with
of 0, 1%, or 2% DSS in drinking water. Days 28 to 33: some mice were treated with a second cycle of DSS. Mice were imaged by MRI
multiple times throughout the study. MR indicates the imaging time points used to generate Figure 3.
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(IV; 0.2 mmol/kg for a 20-g mouse) at a rate of 150 μl/min. FC-77
Fluorinert (3M, Minneapolis, MN) was used undiluted.
Magnetic Resonance Colonography
Animals were fasted except for drinking water for 12 hours be-
fore the MRC. Magnetic resonance colonography was performed
on an Intera Achieva 3.0-T clinical scanner (Philips Medical Systems,
Cleveland, OH) equipped with Philips 1.5.4 software and a dedi-
cated mouse solenoid receiver coil. A physiologic monitoring system
(Small Animal Instruments, Inc., Stoney Brook, NY) enabled the main-
tenance of constant temperature and airflow in the anesthesia chamber,
a 38-mm OD × 254-mm length clear plastic tube that provides both
hearing protection and access for anesthesia gases. It has ports for anes-
thesia gas, waste gas, and catheter line for IV injection and tubing for
the enema. The mice were anesthetized by inhalation of 3% isoflurane
and maintained on a mixture of isoflurane/O2 (1%/1.25%, v/v)
throughout data collection. A 20-G gavage syringe was used to deliver
an enema containing 0.6 ml of FC-77 Fluorinert (3M) or water. The
enema tubing was connected to a syringe pump and maintained at a
continuous rate of 25 μl/min to keep the colon distended during the
imaging procedure.
T2- and T1-weighted image sequences were applied in the coronal
plane with a field of view (FOV) covering the entire colon. A three-
dimensional (3D) T2W turbo spin echo image acquisition (time repe-
tition [TR] = 2000 milliseconds, echo time [TE] = 65 milliseconds,
turbo spin echo factor = 28, matrix = 256 × 178, FOV = 50 ×
35 mm, number of coronal slices = 94, slice thickness = 0.2 mm, scan
time = 17 minutes) was synchronized with the respiratory cycle to
minimize motion artifacts. A 3D T1W fast field echo imaging was
performed (TR/TE = 15/3.3 milliseconds, flip angle = 25°, matrix =
256 × 178, FOV = 50 × 35 mm, coronal slices = 94, slice thickness =
0.2 mm, scan time = 17 minutes) before and after IV contrast in-
jection. After the first scan, 50 μl of Magnevist followed by 50 μl of
phosphate-buffered saline was infused at a rate of 150 μl/min into the
tail vein through a catheter using a syringe infusion pump (BS-9000-8;
Braintree Scientific, Braintree, MA) followed by T1W postcontrast
scans. The isotropic resolution allows multiplanar reformation (MPR)
of coronal images after the acquisition.
Data Analysis and Tumor Volume Calculations
Data were collected from more than 66 different mice, which were
imaged in 134 MRI sessions, where each session included multiple
imaging sequences. The data included 40 control sessions, 40 ses-
sions from mice treated with one cycle of 2% DSS, 41 sessions from
mice after the second cycle of 2% DSS, seven sessions from mice
after one cycle of 1% DSS, and six sessions after two cycles of 1%
DSS. To quantitatively assess of the signal intensities (SIs), regions
of interest (ROIs) were placed in the lumen and in adjacent tissue.
Image noise was determined from an ROI placed outside the animal
and defined as the SD of the SIs. The signal-to-noise ratio (SNR) was
determined as SIlumen / noise. The contrast-to-noise ratios (CNRs)
was determined as (SIlumen − SImuscle) / noise. Multiple 0.2-mm slices
from coronal images that spanned the entire colon were used to gen-
erate each ROI, which were manually drawn around tumors in each
slice using the National Institutes of Health’s ImageJ [10] software,
and the volume of each lesion was calculated. The sum of the vol-
umes of contiguous tumor ROIs was tabulated. For comparison, vol-
ume measurements of colonic lesions were also estimated ex vivo.
After euthanasia, colons were removed and opened to expose the
lumen. Volumes were measured on tumors with clear boundaries
in three dimensions using calipers where vol = πr2h.
Results
Experimental Colitis Detected by MRI
DSS added to the drinking water for 5 to 7 days induces an
inflammatory response in mouse colon that resembles colitis in hu-
mans [11]. At 2 to 3 days after a 5-day exposure to DSS, the colon
was imaged by T2W and T1W MRI sequences in the coronal plane
without and with intravenous contrast agent. In the normal colon,
the distal 2 cm of the descending colon was usually depicted
(Figure 2A) and the SI was similar to other organs of the abdominal
cavity. The lack of water in the stool results in a dark image in T2W
(ST). The rectal colon (R) was depicted as it passes though the pelvic
region to the anus.
After 5 days of exposure to 2% DSS in the drinking water, the
mice showed signs of acute inflammation, as indicated by weight
loss, diarrhea, and spotty bleeding. The increased luminal fluids re-
sulting from the inflammatory response is shown in Figure 2B. The
inflammatory fluid, which has a more intense signal on T2W images,
resulted in distention of the colon. The CNR for lumen of the
untreated mouse was approximately 11, whereas 3 days after DSS
exposure, the CNR for the treated mouse was 25 (Figure 2, T2W
panels). The distention of the fluid-filled lumen was also visible on
T1W images as a hypodense lumen. The increased luminal fluid was
even more apparent on T1W images after IV contrast agent. Inter-
estingly, after injection of contrast media, there was an increase in the
intralumenal signal indicating leakage of Gd-DTPA into the lumen
due to enhance vascular leakiness. The contrast agent fills the lumen
from the ascending and transverse colon distally (Figure 2B, right
panel red arrowhead). Thus, the increased SI of the colonic wall in
acute colitis in this mouse model is consistent with an increase in
secreted intralumenal fluid and suggests a strong inflammatory re-
sponse. Acute inflammation was confirmed by hematoxylin and eosin
(H&E) staining of tissue harvested just after imaging (Figure 2D). The
acute inflammation resolved 9 days after exposure to DSS (Figure 2C)
as indicated by the decrease in the CNR from 25 (Figure 2B) to 16
(Figure 2C) in this mouse.
Detection of Colonic Tumors by MRC with Fluorinert Enema
and Intravenous Gadolinium Chelate
Imaging the nondistended colon by MRI is difficult owing to the
collapse of the colonic walls. Contrast-enhanced T1W imaging
enhances signal from the colonic wall and improves SNR. However,
without bowel distention, T1W imaging was insufficient to discrim-
inate the wall from the luminal contents (Figure 2A). Administra-
tion of water enemas has been used to distend the colon and create
a dark lumen [12]. Initially, enemas containing water or Fluorinert,
neither of which produce signal in T1W, were compared. The SNR
for Fluorinert enema of 0.9 indicated that very little to no signal was
being detected from the Fluorinert. Conversely, the SNR for the water
enema was 6.5 indicating a modest amount of signal from the water
(Figure W1). Moreover, administration of 0.6 ml of Fluorinert by
enema just before MRI expanded the lumen and created a dark lumen
on both T1W and T2W images, which was not possible with water
(Figure 3A). The use of the Fluorinert enema for dark lumen MRC
provided clear images of the colon from the rectum through the
ascending colon. The dark lumen also aided in the depiction of tumors
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(Figure 3B). The lumen of a mouse 58 days after exposure to AOM/
DSS was clearly distended by the Fluorinert enema, and the tumors were
distinguishable. As previously reported, dark lumen MRC plus IV
contrast media provided the optimal CNR, allowing the clear de-
lineation of tumors in the colon [12].
Three-dimensional MR Images Allow MPR of the Colon
Multiplanar reformation of the coronal images allowed reconstruc-
tion in the axial and sagittal planes (Figure 3C ). The integrity of the
mucosal lining was best depicted on the axial plane. In the control
animal, the mucosal lining was seen as a uniform layer (Figure 3C ,
a-a and b-b). During the later stages of tumor progression, the thick-
ness of the mucosa and its enhancement pattern was no longer
uniform (Figure 3C , c-c and d-d ). The lack of continuous contrast
enhancement of the mucosal lining seen in the sagittal MPR indi-
cates nonuniform blood flow to the epithelial tissues during tumori-
genesis a potentially important observation about the heterogeneity
of angiogenesis during tumor formation.
Figure 2. Magnetic resonance imaging shows inflammation 3 days after DSS treatment. T2W and T1W image sequences applied in
coronal plane without and with intravenous contrast. Colons were not distended with air or enema. Normal colon (A), inflamed colon
3 days after DSS exposure ended (B), colon recovering from inflammation 9 days after DSS exposure ended (C; T2W only). Red arrows
show the anus (A), the rectum (R), sigmoid colon (SC), descending colon (DC), and the transverse colon (TC); white arrowheads show fat
(F); white arrows show muscle (M), stool (ST), stomach (S), and kidney (K); and red arrowheads in panel B show luminal contrast agent.
(D) Corresponding whole-mount H&E-stained section of colon tissue confirms inflammation 3 days after DSS: normal colon (top panels)
and inflamed colon 3 days after DSS ended (bottom panels). Scale bar, 1 mm.
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Magnetic Resonance Imaging Is Useful for Monitoring
Progression of Inflammation-Induced Colon Carcinogenesis
In FVB/N mice, which are sensitive to AOM/DSS–induced tumori-
genesis, a single cycle of 2% DSS was sufficient to induce inflammation
and subsequent tumor promotion after AOM exposure (Figure 4).
Mice were treated with a single dose of AOM on day 0, followed by
5 days of DSS starting on day 7. Mice were imaged by MRI at various
time points (Figures 1 and 3). All of the images illustrated are from
the same mouse except for the untreated mouse. Significant inflamma-
tion was seen in the colon 3 days (day 15) after DSS treatment was
Figure 3. Fluorinert is used to distend and reduce signal from the lumen of the colon. Representative images from MRI sequences
applied in coronal plane: (A) T2W, T1W, and T1W with contrast-enhanced coronal images in a healthy colon after Fluorinert enema; (B)
T2W coronal images in a tumor-bearing colon: before enema (left panel) and with Fluorinert enema (right panel). (C) Sagittal (top panels)
and axial (bottom panels) views after MPR of postcontrast T1 images: normal colon (left panels) and tumor-bearing colon (right panels).
Subpanels a-a, b-b, c-c, and d-d indicate the same location in each view. Arrowhead shows healthy mucosal lining (a-a and b-b) and
damaged mucosal lining (c-c and d-d).
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completed. In this mouse, intravenous Gd-DTPA was seen leaking into
the colon lumen and apparently mixing with the Fluorinert. This
mouse also showed weight lost and bloody stools, consistent in acute
colitis. The degree of mixing of the contrast agent (hyperintense signal)
with the Fluorinert (hypointense signal) increased during the 17 min-
utes needed for the collection of the images and varied among mice
receiving the same treatment (data not shown). In addition, because
the mice were more sensitive to the pressure of the enema within the
first 3 days after DSS treatment and the possibility of bowel perforation
was increased, the use of the enema to monitor acute inflammation was
discontinued during the acute phase.
By day 21, 9 days after DSS was completed, the acute inflam-
mation had subsided and the lumen of the colon was again clearly
defined by the Fluorinert enema. The mice gained weight, rectal
bleeding had stopped, and the mice were able to tolerate the enema.
There appeared to be an increase in blood flow to the mucosa as in-
dicated by the increase in contrast enhancement in this area (arrow-
head). By day 29, the degree of inflammation decreased and only a
small amount of contrast agent was detected in the epithelial lining.
At this early time, tumors (seen as asymmetric mounds of tissue)
were detected at various locations in the colon. Typically, the tumors
measured 2 to 3 mm3 and extended into the lumen 0.6 to 1.0 mm.
By day 54, some of these tumors had grown as large as 25 mm3 and
extended 1.4 to 1.6 mm into the lumen. New tumors were also de-
tected at this time. By day 63, the tumor burden became unsus-
tainable, and the mice were euthanized. Axial MR colonographic
views depict the increase in contrast enhancement and the degree
of tumor growth into the lumen (Figure 4B). Whereas most mice
developed tumors in a similar time course, detection of the initial
tumor and tumor size varied between mice (see below and data
not shown). No visible tumors were detected on multiple images
in control mice, treated with AOM but not with DSS, suggesting
Figure 4. Magnetic resonance colonography is useful for monitoring the progression of inflammation-induced colon carcinogenesis.
(A) Mice were imaged with T2W images followed by T1W images before and after contrast. Representative coronal images from
T1W MRI sequences after contrast are shown. Except for control, images are from the same mouse imaged on days 15, 21, 29, 54,
and 63 after AOM injection. Untreated mouse was injected with AOM but did not receive DSS and was imaged on day 39. Day 15 shows
inflammation (contrast bleeding into lumen). Day 20 shows that inflammation has resolved and contrast enhancement of mucosal
lining (arrowhead). Day 29 shows beginning of tumor growth (white arrows). Day 50 shows that the same tumors have grown (white
arrows) and new tumors have formed. Day 60 shows mouse just before euthanasia. (B) Axial views after multiplanar reformatting of
postcontrast T1 images.
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that repeated Fluorinert enemas and/or MRI did not promote tumori-
genesis (Figure 4B and data not shown).
Imaging by MRI Correlates with Ex Vivo Digital Images
The standard end point for measuring tumors in this model is
20 weeks (140 days) after exposure to AOM/DSS. At this time, co-
lonic neoplasms adenomas and adenocarcinomas, with dysplastic
lesions, mucosal ulcers with focal dysplasia and ACF can be seen his-
tologically [5]. Using MRI, tumors were detected as early as 29 days
after AOM (Figure 4). Unfortunately, FVB/N mice are very sensitive
to the AOM/DSS treatment, and many mice developed anal prolapse
due to their tumors and had to be euthanized before the 20-week end
point. For instance, the progression of tumor growth shown for the
mouse in Figure 4 was terminated 9 weeks after AOM injection.
After MRC, the colons were removed from the animals and fixed
intact. Slices were cut at the approximate distance from the rec-
tum corresponding to the MRI section that demonstrated the lesion
(Figure 5, A–C ). The H&E-stained slides show the presence of the
tumors at the estimated locations determined by MRC.
Figure 5, D–F, shows a digital photograph of the colon opened to
expose the lumen and the H&E staining of tissue taken from this
colon. The corresponding tumors seen by MRI are indicated with
red arrows. Multiple 0.2-mm MR images confirm the extensive tumor
burden seen. Tumor 1 (T1), the most distal tumor, was most consis-
tent with a carcinoma in situ. The tumor was endophytic with mild
invasion of the submucosa by high-grade dysplastic glandular foci that
were distinct from the primary tumor. High-grade dysplasia consisted
of mild nuclear pleomorphism, increased mitoses, loss of nuclear po-
larity, and hyperchromasia. Other lesions in the distal colon had evi-
dence of low-grade dysplasia and polyp formation. Low-grade dysplasia
consisted of disorganization of epithelia glands, epithelial hyperplasia
with increased mitoses, stratification of nuclei in glands, and loss of
goblet cells. Polyps were formed by the dysplastic glands and inflam-
matory cells. Inflammation was primarily chronic consisting of large
numbers of lymphocytes and plasma cells with fewer neutrophils.
A representative volume measurement of multiple tumors from two
animals and the corresponding volume determine by caliper measure-
ments are shown in Figure 6A. For the eight tumor volumes calculated
from MRI in vivo, the volume measured ex vivo was significantly cor-
related with each other. Because of the irregular shape and overlapping
nature of many of the tumors, an accurate measurement by MR or by
caliper for all the tumors was not possible. Figure 6B also shows a time
course of tumor growth for a single animal. Tumor volumes were
determined in the same animal at day 35 and again at day 58. In this
mouse, tumor no. 2 measure 1.2 mm3 on day 35. By day 58, tumor
no. 2 had more than doubled in size. It is clear from the MR image
that the tumors grow at different rates.
Discussion
The present study describes a method for imaging the early stages
of CRC in a mouse inflammation-carcinoma model using a 3.0-T
clinical MRI scanner equipped with a dedicated mouse solenoid
receiver coil. The use of the Fluorinert enema allows dark lumen
imaging by T1W imaging with and without intravenous contrast as
well as by T2W imaging. Using T2W MRI in combination with a
contrast-enhanced T1W dark lumen MRI, the early stages of tumori-
genesis, starting with inflammation, through the advanced tumor
growth was followed over time in the same mouse. In the early stages,
T2W MRI was used to detect acute inflammation 2 to 3 days after
DSS exposure. During this period, the bowel wall was relatively stiff
because of the inflammation and was already distended with secretions
so that the Fluorinert enema was not necessary. By 7 to 9 days, the
inflammation had subsided and the Fluorinert enema became neces-
sary to render the lumen totally dark while sufficiently distended to
allow direct depiction of the mucosal wall. Intravenous injection of a
gadolinium contrast agent and T1W imaging highlighted the changes
in the epithelial lining due to chronic inflammation, hyperplasia, and
destruction of the mucosal layer. Tumors as small as 1.2 mm3 and as
early as 29 days were detected after initiation. Individual tumor growth
was followed during the course of the study, and volume measure-
ments from MRC in vivo correlated with caliper measurements of
the tumors ex vivo.
Early detection remains the best method of reducing mortality from
CRC. The use of animal models allows the design of new and safer
methods to screen for early signs of colon cancer. In addition, these
models will expand the understanding of the molecular events leading
to tumor formation and could help identify new response indicators
that correlate with the early stages of tumorigenesis. Finally, these ani-
mal models allow preclinical testing of new strategies for prevention
and intervention.
The ability of MRI to detect the early stages of colon cancer in mice
provides a safe, less-invasive method to monitor the effects of new
therapeutics, to determine the optimal time for collection of samples
for molecular analysis, and to correlate response indicators to a real-
time response in the animal. Magnetic resonance imaging is more
appropriate in an animal model than CT because the high radiation
doses required for serial mouse imaging during microCT could lead to
unwanted perturbations such as increased DNA damage and tumor
initiation in these models. Moreover, the use of MRI in animal studies
could readily be translated to the clinic. The 3.0-T MRI scanner used
in this study is a clinical scanner that was adapted for mouse studies.
Magnetic resonance colonography for detecting and staging colon
cancer is being explored in the clinic as an alternative to optical
colonoscopy and CT colonography, which are commonly performed
in humans [8,13–15]. For either MR or CT colonography, the colon
needs to be distended to allow reliable imaging of the colon wall for
the assessment of the bowel wall thickness, inflammation, and reli-
able depiction of tumors. Presently, water-based enemas, air, or car-
bon dioxide are used to distend the bowels [8,12,16–18]. Recent
studies comparing water-based dark lumen MRC with colonoscopy
found that the dark lumen MRC was highly accurate in the detection
of colorectal masses. In these studies, colonic lesions exceeding 5 mm
in size were accurately detected with specificity greater than 95%. In
addition, alterations of the colonic wall associated with diverticulitis
and inflammatory bowel disease were also detected [12,16]. Lumen
distention with CO2, which may offer less distortion and dephasing
artifacts, was used to detect colonic lesions with dark lumen MRC
[18]. In addition to distending the colon, a high contrast between
the mucosal lining and the lumen is critical for an accurate measure-
ment of tumors. Water enemas are also used for bright lumen MRI
where T2W images produce a dark-appearing mucosal wall in a bright
lumen background. A gadolinium-based enema combined with T1W
images will also produce the bright lumen background. Whereas a
gadolinium enema bright lumen MRC allowed a high sensitivity rate,
this method has difficulty differentiating between the mucosal lining,
residual fecal material, and air bubbles from colonic masses [16]. In
the present study, a bright or signal-intense wall with a dark lumen
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Figure 5. Comparison of MRC with histopathology. Optical photography of the colon ex vivo shows multiple tumors. (A–C) Axial MPR
and corresponding ex vivo images: axial view from MPR (A), optical photography of the same colon shortly after MRI (B), and H&E-
stained tissues (C). Locations of tumors were estimated from MRI with ImageJ software. Tissue slices were taken at the corresponding
distance from the rectum in the extracted colon. Red arrows indicate estimated location for acquisition of images. Hematoxylin and
eosin from untreated control animals are from distal (left) and proximal (right) colon. (D–F) Tumors depicted in coronal view correspond
to tumors seen in excised colon with lumen exposed: coronal MRI (D), photograph of the exposed lumen (E), and H&E-stained tissue (F).
Tissue slices were taken at the corresponding distance from the rectum in the extracted colon (red arrows). Scale bar in H&E, 2 mm.
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background was obtained with both T1W and T2W imaging after
distention with Fluorinert, which, unlike water enemas, produced
no signal to noise background. Additional contrast was provided by
intravenously injected gadolinium chelates, which enhance the colon
wall and tumors.
Previous studies demonstrated the value of MRC in the ApcMIN
mouse model using a 7-T MRI with a Bruker DRX300 console to
image tumors in the colon. A Gd-DTPA–filled silicone tube was used
to aid in the identification of the tumors. Whereas tumors as small at
1.5 mm3 were detected, repeated imaging to follow progression was
not reported [19]. In the present study, a Fluorinert enema was used
to distend the mouse colon without trauma to the intestinal mucosa.
Fluorinert is ideal for dark lumen MRI because it is dark on both
T1W and T2W images. Perfluorochemical such as Fluorinert have a
high safety profile; they have been safely used for partial liquid venti-
lation of critically ill premature infants with severe respiratory distress
syndrome, and clinical trials to assess the use of perfluorochemical for
liquid ventilation have been reported [20,21]. The repeated use of the
Fluorinert enema in mice resulted in no detectable toxicity or injury to
the bowel. Mice, which were treated with AOM alone and therefore
not expected to produce tumors, did not produce tumors even after
receiving one or more Fluorinert enemas, suggesting that no additional
inflammation was induced by Fluorinert. Although some of the mice
with acute inflammation up to 3 days after DSS exposure did not toler-
ate the enema, most likely due to the pressure of the enema on the
compromised mucosal wall, repeated use of the Fluorinert enema at
all other times resulted in no detectable toxicity or injury to the bowel.
Whereas it is not known whether Fluorinert can cross the epithelial
barrier of the colon, there were no visible indications that the enema
was creating an inflammatory response in the epithelial tissue.
To efficiently translate information obtained from mouse models of
human cancer, it is crucial to incorporate technologies that can rapidly
monitor disease progression without requiring the sacrifice of animals
at each step. By using minimally invasive methods for detecting and
monitoring tumor growth that could be used in the clinic, information
derived from the mouse model can more rapidly be translated to the
clinic. Magnetic resonance colonography provides a safe and reproduc-
ible method for early depiction of premalignant lesions in the mouse
colon. The information and efficiencies gained by studying mouse
models of colon carcinogenesis with noninvasive imaging techniques
such as MRC could accelerate the development of interventions that
interrupt the sequence of cancer development in the colon. These in-
terventions might find their way earlier into clinical trials, using imag-
ing techniques similar to those described here.
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Figure W1. T1W images of mouse colon after water or Fluorinert enema.
